GLP1R and steatosis: Finally, GLP-1 Ras may offer therapeutic potential for nonalcoholic steatohepatitis (NASH) by reducing hepatic inflammation, steatosis, and fibrosis, although the exact mechanisms underlying these effects remain to be elucidated [65].